Patricia A. Pioli

TL;DR: These drugs suppressed the production of nitric oxide and a variety of inflammatory cytokines, including IL-6, CCL2, and GM-CSF, in both immune and pancreatic cancer cells in vitro.

TL;DR: The approach provides a framework for examining molecular signatures of disease in fibrosis and autoimmune diseases and for leveraging publicly available data to understand common and tissue-specific disease processes in complex human diseases.

TL;DR: Molecular changes during MMF therapy that suggest reduction of innate immune cell numbers, possibly by attenuating expression of chemokines, including CCL2, are summarized.

TL;DR: The activation profile of SSc monocyte‐derived macrophages is characterized and their interaction with SSc fibroblasts is assessed to characterize the activity of these cells in systemic sclerosis.

TL;DR: Further work is needed to address macrophage subset heterogeneity within and among SSc end-target tissues to determine the disparate functions mediated by these subsets and to identify additional targets for therapeutic intervention.